This site is intended for healthcare professionals
Latest drug news
  • Home
  • /
  • News
  • /
  • 2018
  • /
  • 04
  • /
  • CE Mark for CoAp Pro device for treatment of mitra...
Drug news

CE Mark for CoAp Pro device for treatment of mitral valve repair.- HeartStitch

Read time: 1 mins
Last updated:24th Apr 2018
Published:24th Apr 2018
Source: Pharmawand

HeartStitch has received its CE Mark in the European Union for its CoAp Pro device for treatment of mitral valve repair. This approval will provide physicians the ability to remodel the leaflets of the mitral valve and reestablish proper coaptation. The CoAp Pro expands HeartStitch's product line of cardiovascular devices, increasing the ability to provide surgeons and interventional cardiologists with a toolbox of solutions for treatment.

Prof. Dr. Achille Gaspardone, Director of Cardiology, Department of Medicine, Ospedale, S. Eugenio � ASL RMC, Rome Italy commented, "I am especially pleased to see HeartStitch receive this approval, because it provides the ability to use suture to remodel the mitral valves rather than the need to place a prosthetic device in the leaflets. In my opinion it is a significant advancement to the treatment of Mitral Regurgitation. Personally, I have seen the development of this device from its inception and have participated in the clinical testing, and with my extensive experience with the use of the NobleStitch� EL for PFO closure it was a natural evolution for me to use this technology."

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.